The Great Eye Care Split: MyEyeDr. Absorbs 300 Clinics in PE Restructuring

VIENNA, Va. – September 28, 2026 – To the casual observer, the consolidation of neighborhood storefronts happens quietly, marked only by a new logo on the door or a subtle shift in the eyewear brands lining the walls. But in the boardrooms of private equity sponsors, these shifts are tectonic, driven by billions in leveraged debt and the relentless pursuit of scale.

Today's announcement that MyEyeDr. will acquire the optometry division of EyeCare Partners (ECP) is a prime example of this underlying mechanical shift. The transaction will absorb more than 300 practice locations across the United States, sweeping up prominent regional brands including Clarkson Eyecare, Nationwide Vision, EyeCare Associates, EyeCare Center, and The Eye Doctors.

For MyEyeDr., which operates under the Goldman Sachs and Charlesbank-backed parent entity Capital Vision Services, the deal expands an already massive footprint to over 1,200 locations across the country.

“MyEyeDr. was founded 25 years ago to combine industry-leading optometric eye care with world-class products and convenient support services,” MyEyeDr. co-founder and CEO Sue Downes said in a statement. “Today I am proud to share the news of MyEyeDr.'s continued growth throughout the US, reinforcing our commitment to access to care, and a shared passion of helping patients no matter their unique vision, health, or financial needs.”

EyeCare Partners will retain its network of ophthalmology clinics and ambulatory surgery centers, effectively separating its medical-surgical operations from primary retail optometry.

“Bringing our organizations together is a major milestone in growing the profession of optometry while expanding access to high-quality, neighborhood-based care,” noted EyeCare Partners CEO Chris Throckmorton, adding that his organization sought a partner with a commitment to clinical excellence to support the next phase of growth.

Yet, beyond the polished corporate statements about patient access and shared best practices, this carve-out transaction exposes the structural breakdown of the "integrated eye care" thesis that dominated private equity roll-ups over the last decade, and the severe debt pressures forcing a strategic retreat.

The Debt-Driven Unraveling of the Integrated Model

To understand the strategic rationale behind this acquisition, one must look at the balance sheet of the seller. EyeCare Partners, acquired by Swiss private equity giant Partners Group in a $2.2 billion buyout in late 2019, has spent the last several years buckling under the weight of aggressive, debt-funded expansion.

By 2024, ECP had accumulated over $2.1 billion in debt. Rising interest rates, wage inflation, and post-pandemic integration hurdles severely constrained cash flow, prompting a controversial uptier liability management transaction that same year. Despite raising super-priority new money, the underlying leverage remained unsustainable. In December 2025, S&P Global Ratings downgraded the company to 'CCC-' with a negative outlook, warning that the company's cash interest burden would surge by nearly 45 percent in January 2027 when a payment-in-kind (PIK) toggle on its $1.495 billion second-out term loan expires.

Faced with distressed debt trading below 45 cents on the dollar, ECP needed a lifeline. The divestiture of its 300-clinic optometry division to MyEyeDr.—estimated by healthcare financial analysts to be valued between $650 million and $950 million based on current EBITDA multiples—provides the necessary capital to execute an out-of-court balance sheet deleveraging.

But the split also represents an admission of operational defeat. For years, private equity sponsors believed that acquiring primary care optometrists would create an internal, vertically integrated feeder system for their highly profitable surgical ophthalmology centers.

The reality proved far more complex. As one healthcare investment banker familiar with the carve-out noted privately, the vertical integration dream looked brilliant on a spreadsheet, but sponsors underestimated the fierce independence of community optometrists. Many acquired doctors resisted mandated corporate referral loops, preferring to send patients to outside surgeons based on established clinical trust. ECP found itself bearing the heavy administrative overhead of retail optical shops without capturing the intended surgical yield.

Ultimately, the business models were fundamentally incompatible. Optometry is a retail, foot-traffic, and managed-care volume game with margins hovering between 12 and 18 percent. Ophthalmology is a tertiary medical-surgical model driven by ambulatory surgery center facility fees and Medicare Part B billing, boasting margins up to 40 percent. By carving out optometry, ECP can return to being a pure-play specialty surgical organization, while MyEyeDr. absorbs the retail volume it is specifically engineered to process.

Antitrust Crosshairs and Geographic Hotspots

While the financial logic is sound, the regulatory path is fraught. The acquisition is slated to close in the fourth quarter of 2026, but it must first navigate an increasingly hostile federal enforcement climate.

The transaction easily exceeds the Federal Trade Commission's $133.9 million Hart-Scott-Rodino (HSR) reporting threshold for 2026, requiring mandatory premerger notification. Regulators will evaluate market power at the local Metropolitan Statistical Area (MSA) level, utilizing the stringent 2023 FTC/DOJ Merger Guidelines.

The geographic overlap presents several high-risk concentration hotspots. In North Carolina, where MyEyeDr. already operates one of its most concentrated legacy retail hubs, the absorption of roughly 60 eyecarecenter locations will trigger immediate regulatory scrutiny. Similar localized market share red flags exist in the Midwest, where Clarkson Eyecare's 150-plus locations overlap heavily with MyEyeDr.'s suburban footprint in Ohio and Illinois, as well as in Central Florida with The Eye Doctors.

If the FTC or the Department of Justice issues a Second Request for information, the review timeline could easily drag into mid-2027. This would place immense pressure on ECP's pending debt restructuring deadlines. Furthermore, the deal arrives just months after the House Oversight Committee launched an investigation into the vision care sector, probing how vertical integration among retail chains and vision benefit managers harms consumer pricing.

Main Street Mechanics: The Impact on Clinicians and Consumers

For the patients and clinicians operating at the ground level of these 300 practices, the transition from one corporate parent to an even larger mega-group carries tangible implications.

MyEyeDr. brings unmatched scale to the retail optometry space. With over 1,200 locations, the company commands centralized optical supply chain contracts, in-house lens finishing capabilities, and immense leverage when negotiating with managed vision plans like VSP and EyeMed. However, this corporate efficiency frequently alters the traditional doctor-patient dynamic.

To sustain profitability in a retail-first model, corporate platforms typically institute standardized 15- to 20-minute patient exam slots. Practitioner groups have quietly expressed concerns that compressed scheduling limits the time necessary for comprehensive medical pathology assessments, such as diabetic retinopathy screenings or complex dry eye treatments.

Furthermore, compensation structures for employed optometrists are often tied directly to retail key performance indicators. Doctors and clinical staff are measured on optical dispensary conversion rates, anti-reflective coating attachments, and annual contact lens supply sales. For the consumer, this can translate to an aggressive sales environment on the showroom floor, where high retail markups on designer eyewear and out-of-pocket upgrade charges are utilized to offset the thin clinical margins allowed by vision benefit managers.

Patients who previously relied on Clarkson Eyecare or Nationwide Vision for both their annual checkup and a seamless internal referral to an ECP ophthalmologist will now have to navigate two entirely disconnected corporate entities. The continuity of care—once the primary selling point of the integrated platform—has been sacrificed to satisfy the demands of the credit markets. As the ink dries on this massive acquisition, the quiet mechanics of private equity continue to redraw the map of American healthcare, one local clinic at a time.